Assesment of the Metabolomic Signature in COVID-19 Patients
NCT ID: NCT04497272
Last Updated: 2022-08-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
150 participants
INTERVENTIONAL
2020-08-07
2022-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Caracterisation of COVID-19 Patients Hospitalized in Infectious Disease Department
NCT04779021
Health Professional Exposure Assessment to Covid-19
NCT04429724
Human Ab Response & immunoMONItoring of COVID-19 Patients
NCT04373200
Development and Qualification of Methods for Analyzing the Mucosal Immune Response to COVID-19
NCT06142279
Relation Between Lab Finding and COVID-19 Severity
NCT04470557
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
The metabolomic signature of COVID-19 patients
It will consist in the collection of 1 additional tubes at their blood draw and 1 urine sample.
COVID-19 patients
It will consist in the collection of 1 additional tubes at their blood draw and 1 urine sample.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
COVID-19 patients
It will consist in the collection of 1 additional tubes at their blood draw and 1 urine sample.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* affiliated to a social security scheme
* consultant in the emergency department and/or being hospitalized for suspected SARS CoV infection
* confirmation, after medical examination, of the need for a biological examination (this will negate the need for additional venipuncture)
* Person subject to a guardianship order
* Opposition to the use of the data or samples (withdrawal of non-opposition) / Sponsor's or investigator's decision
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Nice
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
OCCELLI Céline
Role: PRINCIPAL_INVESTIGATOR
Néphrologie, CHU de Nice
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de nice
Nice, Alpes-Maritimes, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20-PP-18
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.